Several novel signaling proteins were identified, including PRKDC (DNA-dependent protein kinase, catalytic subunit, DNA-PKcs), PRKAA2 (5′-AMP-activated protein kinase catalytic subunit alpha-2), PTK2 (protein tyrosine kinase 2), and RPS6KA4 (ribosomal protein S6 kinase alpha-4), as possible therapeutic targets and/or biomarkers in PCa. Here, PRKAA2 is linked to posterior cortical atrophy.